Mayo specialist for Cytopia
Wednesday, 30 July, 2008
Cytopia [ASX: CYT] has appointed a study chair for Phase I clinical trials of its new JAK2 enzyme inhibitor.
Dr Ayalew Tefferi is professor of medicine in haematology at the Mayo Clinic College of Medicine in the US.
JAK2 is a mutant enzyme which occurs in myelofibrosis patients, a disorder which causes bone marrow to be replaced by fibrous scar tissue. JAK2 can also cause other blood disorders, many of which can lead to conditions such as leukemia.
Cytopia expects to be ready to file an Investigational New Drug application for the treatment with the US FDA by the end of the year.
Frequent nightmares accelerate aging, increase risk of death
Nghtmares independently predict faster biological aging and earlier mortality — even after...
Cardiac organoids bring hope for treating heart disease
Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...
Indigenous-led initiative to resurrect the South Island Giant Moa
New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...
